Pushkal Garg
CIK: 0001829252
Transaction Breakdown
High conviction signal
Position reduction
Derivative conversions
Compensation grants
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Companies & Roles (1)
ALNYLAM PHARMACEUTICALS, INC.
Discretionary Trading P&L
Holdings
Transaction History (154 total)
- Mar 5, 2026ALNY
ALNYLAM PHARMACEUTICALS, INC.
Sale(S)Direct654 shares at avg. $322.33$211K - Mar 5, 2026ALNY
ALNYLAM PHARMACEUTICALS, INC.
Sale(S)Direct740 shares at avg. $323.55$239K - Mar 5, 2026ALNY
ALNYLAM PHARMACEUTICALS, INC.
Sale(S)Direct510 shares at avg. $324.59$166K - Mar 5, 2026ALNY
ALNYLAM PHARMACEUTICALS, INC.
Sale(S)Direct500 shares at avg. $326.08$163K - Mar 4, 2026ALNY
ALNYLAM PHARMACEUTICALS, INC.
Sale(S)Direct106 shares at avg. $319.03$34K - Mar 4, 2026ALNY
ALNYLAM PHARMACEUTICALS, INC.
Sale(S)Direct767 shares at avg. $323.84$248K - Mar 4, 2026ALNY
ALNYLAM PHARMACEUTICALS, INC.
Sale(S)Direct215 shares at avg. $320.81$69K - Mar 4, 2026ALNY
ALNYLAM PHARMACEUTICALS, INC.
Sale(S)Direct208 shares at avg. $325.67$68K - Mar 4, 2026ALNY
ALNYLAM PHARMACEUTICALS, INC.
Sale(S)Direct102 shares at avg. $320.01$33K - Mar 4, 2026ALNY
ALNYLAM PHARMACEUTICALS, INC.
Sale(S)Direct350 shares at avg. $323.01$113K - Mar 4, 2026ALNY
ALNYLAM PHARMACEUTICALS, INC.
Sale(S)Direct289 shares at avg. $321.82$93K - Mar 4, 2026ALNY
ALNYLAM PHARMACEUTICALS, INC.
Sale(S)Direct272 shares at avg. $324.88$88K - Mar 3, 2026ALNY
ALNYLAM PHARMACEUTICALS, INC.
Sale(S)Direct463 shares at avg. $321.50$149K - Mar 3, 2026ALNY
ALNYLAM PHARMACEUTICALS, INC.
Sale(S)Direct355 shares at avg. $316.74$112K - Mar 3, 2026ALNY
ALNYLAM PHARMACEUTICALS, INC.
Sale(S)Direct317 shares at avg. $319.06$101K - Mar 3, 2026ALNY
ALNYLAM PHARMACEUTICALS, INC.
Sale(S)Direct640 shares at avg. $320.48$205K - Mar 2, 2026ALNY
ALNYLAM PHARMACEUTICALS, INC.
Sale(S)Direct101 shares at avg. $331.93$34K - Mar 2, 2026ALNY
ALNYLAM PHARMACEUTICALS, INC.
Sale(S)Direct87 shares at avg. $330.85$29K - Mar 2, 2026ALNY
ALNYLAM PHARMACEUTICALS, INC.
Sale(S)Direct42 shares at avg. $332.64$14K - Mar 2, 2026ALNY
ALNYLAM PHARMACEUTICALS, INC.
Sale(S)Direct107 shares at avg. $328.71$35K - Mar 2, 2026ALNY
ALNYLAM PHARMACEUTICALS, INC.
Sale(S)Direct182 shares at avg. $329.71$60K - Mar 2, 2026ALNY
ALNYLAM PHARMACEUTICALS, INC.
Sale(S)Direct353 shares at avg. $327.67$116K - Mar 2, 2026ALNY
ALNYLAM PHARMACEUTICALS, INC.
Sale(S)Direct97 shares at avg. $324.65$31K - Mar 2, 2026ALNY
ALNYLAM PHARMACEUTICALS, INC.
Sale(S)Direct277 shares at avg. $325.63$90K - Mar 2, 2026ALNY
ALNYLAM PHARMACEUTICALS, INC.
Sale(S)Direct50 shares at avg. $323.62$16K
| Type | Shares | Price | Ownership | |||
|---|---|---|---|---|---|---|
| Mar 5, 2026 | ALNY ALNYLAM PHARMACEUTICALS, INC. | Sale(S) | 654 | $322.33 | $210,804 | Direct |
| Mar 5, 2026 | ALNY ALNYLAM PHARMACEUTICALS, INC. | Sale(S) | 740 | $323.55 | $239,427 | Direct |
| Mar 5, 2026 | ALNY ALNYLAM PHARMACEUTICALS, INC. | Sale(S) | 510 | $324.59 | $165,541 | Direct |
| Mar 5, 2026 | ALNY ALNYLAM PHARMACEUTICALS, INC. | Sale(S) | 500 | $326.08 | $163,040 | Direct |
| Mar 4, 2026 | ALNY ALNYLAM PHARMACEUTICALS, INC. | Sale(S) | 106 | $319.03 | $33,817 | Direct |
| Mar 4, 2026 | ALNY ALNYLAM PHARMACEUTICALS, INC. | Sale(S) | 767 | $323.84 | $248,385 | Direct |
| Mar 4, 2026 | ALNY ALNYLAM PHARMACEUTICALS, INC. | Sale(S) | 215 | $320.81 | $68,974 | Direct |
| Mar 4, 2026 | ALNY ALNYLAM PHARMACEUTICALS, INC. | Sale(S) | 208 | $325.67 | $67,739 | Direct |
| Mar 4, 2026 | ALNY ALNYLAM PHARMACEUTICALS, INC. | Sale(S) | 102 | $320.01 | $32,641 | Direct |
| Mar 4, 2026 | ALNY ALNYLAM PHARMACEUTICALS, INC. | Sale(S) | 350 | $323.01 | $113,054 | Direct |
| Mar 4, 2026 | ALNY ALNYLAM PHARMACEUTICALS, INC. | Sale(S) | 289 | $321.82 | $93,006 | Direct |
| Mar 4, 2026 | ALNY ALNYLAM PHARMACEUTICALS, INC. | Sale(S) | 272 | $324.88 | $88,367 | Direct |
| Mar 3, 2026 | ALNY ALNYLAM PHARMACEUTICALS, INC. | Sale(S) | 463 | $321.50 | $148,855 | Direct |
| Mar 3, 2026 | ALNY ALNYLAM PHARMACEUTICALS, INC. | Sale(S) | 355 | $316.74 | $112,443 | Direct |
| Mar 3, 2026 | ALNY ALNYLAM PHARMACEUTICALS, INC. | Sale(S) | 317 | $319.06 | $101,142 | Direct |
| Mar 3, 2026 | ALNY ALNYLAM PHARMACEUTICALS, INC. | Sale(S) | 640 | $320.48 | $205,107 | Direct |
| Mar 2, 2026 | ALNY ALNYLAM PHARMACEUTICALS, INC. | Sale(S) | 101 | $331.93 | $33,525 | Direct |
| Mar 2, 2026 | ALNY ALNYLAM PHARMACEUTICALS, INC. | Sale(S) | 87 | $330.85 | $28,784 | Direct |
| Mar 2, 2026 | ALNY ALNYLAM PHARMACEUTICALS, INC. | Sale(S) | 42 | $332.64 | $13,971 | Direct |
| Mar 2, 2026 | ALNY ALNYLAM PHARMACEUTICALS, INC. | Sale(S) | 107 | $328.71 | $35,172 | Direct |
| Mar 2, 2026 | ALNY ALNYLAM PHARMACEUTICALS, INC. | Sale(S) | 182 | $329.71 | $60,007 | Direct |
| Mar 2, 2026 | ALNY ALNYLAM PHARMACEUTICALS, INC. | Sale(S) | 353 | $327.67 | $115,668 | Direct |
| Mar 2, 2026 | ALNY ALNYLAM PHARMACEUTICALS, INC. | Sale(S) | 97 | $324.65 | $31,491 | Direct |
| Mar 2, 2026 | ALNY ALNYLAM PHARMACEUTICALS, INC. | Sale(S) | 277 | $325.63 | $90,200 | Direct |
| Mar 2, 2026 | ALNY ALNYLAM PHARMACEUTICALS, INC. | Sale(S) | 50 | $323.62 | $16,181 | Direct |
1-25 of 154 transactions
About Garg Pushkal
Garg Pushkal (SEC CIK 0001829252) files insider reports with the SEC as EVP Chief R&D of ALNYLAM PHARMACEUTICALS, INC. (ALNY).
Signal8 holds 15 ownership filings by Garg Pushkal, all Form 4s, filed between Oct 10, 2024 and Mar 6, 2026. Those filings report 154 transactions, from Oct 8, 2024 to Mar 5, 2026. Signal8's Form 4 history starts in Sep 2024.
The business address on Garg Pushkal's filings is in CAMBRIDGE, MA.
Recent filings by Garg Pushkal
Other insiders filing for ALNYLAM PHARMACEUTICALS, INC. (ALNY)
- SUPRAN BRYAN, EVP, CLO and Secretary
- Greenstreet Yvonne, Chief Executive Officer
- PYOTT DAVID E I, Director
- Cravatt Benjamin, Director
- Sigal Charles Elliott, Director
- SCHULMAN AMY W, Director